How to Manage Your Board as a First-Time CEO

The board can be an unknown quantity for a new chief executive. Robert Leeming finds out how to
ensure the relationship is strong, transparent and focused on what’s best for the business.

Key Points:

  • Communicating with a wide range of personalities on the board
  • Changing the format of how a CEO reports to the board
  • Understanding how to arrange your material as a CEO and where to focus discussions 
  • As a Chairman, setting expectations from the start, including the initial agenda and priorities 
Featuring Commentary From: 

David Harding, 

Nigel Howell, Chief Executive, FirstPort

 
Mike Regnier, CEO, Yorkshire Building Society Group

 




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
Responsible AI at Eightfold

Artificial Intelligence, a force with the potential to revolutionise various aspects of people's lives and business operations, demands responsible and ethical decision-making. This is particularly crucial in HR. Cr...

Click here to download this insight
HR Director Research Results ...

This research, conducted at our HR Director Retreat, highlights the executive focus on business performance and ensuring the right leadership capabilities are in place to drive change and success. Key findings from C...

Click here to download this insight
Steering Change at Rolls-Royc...

Sarah Armstrong, Chief People Officer at Rolls-Royce, talks to Senior Editor Bridgette Hall at Criticaleye about guiding the company’s workforce through transformation, focusing on skills and capabilities and her ...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 1,061




Redwood Bank Robert Walters Drax Group plc NATS Concentrix London Stock Exchange Salesforce Workday Lightsource bp Veolia Water Technologies Tullow Oil plc Accenture AlixPartners Eightfold AI LDC Google Mayborn Group Legal & General Investment Management Amazon UK Eton Bridge Partners Bunzl plc E.ON UK Royal London Group GlaxoSmithKline plc